Advertisement

Radiologists look toward future in 3-D printing

By Adam Rubenfire  |  November 26, 2016

The role of 3-D printing in transforming the practice of radiology will be highlighted during the Radiological Society of North America's annual meeting in Chicago, which runs through Dec. 1.

Abbott's hellacious deal gets even worse

Abbott's hellacious deal gets even worse

By Joe Cahill, Crain's Chicago Business  |  November 10, 2016

Hostilities are intensifying in the misbegotten matchup of Abbott Laboratories and Alere. The two medical products companies haven't stopped fighting since shortly after Abbott agreed in January to buy Alere for $5.8 billion.

Henry Ford, Spectrum Health selected for human genome project to study diseases

Henry Ford, Spectrum Health selected for human genome project to study diseases

By Jay Greene, Crain's Detroit Business  |  October 14, 2016

Detroit's Henry Ford Health System has been selected as one of several provider organizations to receive a share of a five-year, $5.5 million federal grant to lead data collection on a project that is part of the human genome research and precision medicine program.

Report finds medical products influence patient satisfaction

Report finds medical products influence patient satisfaction

By Adam Rubenfire  |  September 15, 2016

Patient satisfaction isn't just about the way patients are treated by physicians and staff. The equipment and products used in healthcare facilities can have a significant impact on patient opinion, according to an industry report.

Alere sues Abbott Laboratories to complete $5.8 billion merger

By Erica Teichert  |  August 29, 2016

Abbott waffled on its commitment to purchase Alere in April because of concerns about the accuracy of Alere's statements and representations in the agreement. The North Chicago, Ill., company this month warned that it may not go through with the proposal.

EpiPen price backlash comes as consumers pay greater share

EpiPen price backlash comes as consumers pay greater share

By Adam Rubenfire  |  August 25, 2016

The controversy surrounding Mylan's EpiPen pricing suggests drugmakers have been slow to adapt to an environment in which millions of Americans must pay thousands of dollars out of pocket before their coverage kicks in.

Innovations: Startup's liquid biopsies match cancer patients with trials

Innovations: Startup's liquid biopsies match cancer patients with trials

By Erica Teichert  |  August 20, 2016

Guardant Health, based in Redwood City, Calif., developed a liquid biopsy blood test that has helped match cancer patients with clinical trials and treatment options without costly or invasive biopsies. CEO and co-founder Helmy Eltoukhy calls it a “game changer” for oncology.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.